CLEC1B and neoplasm: Although blocking podoplanin inhibits tumor cell metastasis, platelet-targeting CLEC-2 inhibitors might be preferred as they reduce hematogenous metastasis rates without a significant increase in bleeding risk (149) (Figure 4).